- Home
- INKT vs RVPH Comparison
INKT vs RVPH Comparison
Compare INKT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- RVPH
- Stock Information
- Founded
- INKT 2017
- RVPH 2006
- Country
- INKT United States
- RVPH United States
- Employees
- INKT N/A
- RVPH N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- RVPH Health Care
- Exchange
- INKT Nasdaq
- RVPH Nasdaq
- Market Cap
- INKT 28.8M
- RVPH 32.8M
- IPO Year
- INKT 2021
- RVPH N/A
- Fundamental
- Price
- INKT $62.86
- RVPH $0.40
- Analyst Decision
- INKT Strong Buy
- RVPH Strong Buy
- Analyst Count
- INKT 2
- RVPH 5
- Target Price
- INKT $37.50
- RVPH $9.00
- AVG Volume (30 Days)
- INKT 2.4M
- RVPH 3.4M
- Earning Date
- INKT 08-12-2025
- RVPH 08-13-2025
- Dividend Yield
- INKT N/A
- RVPH N/A
- EPS Growth
- INKT N/A
- RVPH N/A
- EPS
- INKT N/A
- RVPH N/A
- Revenue
- INKT N/A
- RVPH N/A
- Revenue This Year
- INKT N/A
- RVPH N/A
- Revenue Next Year
- INKT N/A
- RVPH N/A
- P/E Ratio
- INKT N/A
- RVPH N/A
- Revenue Growth
- INKT N/A
- RVPH N/A
- 52 Week Low
- INKT $4.56
- RVPH $0.30
- 52 Week High
- INKT $76.00
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- INKT 57.39
- RVPH 33.44
- Support Level
- INKT $6.80
- RVPH $0.35
- Resistance Level
- INKT $7.88
- RVPH $0.83
- Average True Range (ATR)
- INKT 0.40
- RVPH 0.06
- MACD
- INKT 0.02
- RVPH -0.01
- Stochastic Oscillator
- INKT 58.86
- RVPH 17.36
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.